Vasamed awarded CE Mark for AcQtrac System

By Lisa Kerner

Erie, Pa., Jan. 4 - Vasamed announced that it received a CE Mark for its AcQtrac System.

The AcQtrac System provides real-time measurements of hemodynamic parameters, allowing physicians to more effectively manage cardiovascular patients.

The AcQtrac System was cleared for use in the United States by the Food and Drug Administration earlier this year.

"Each year, cardiovascular disease contributes to nearly half of all deaths in Europe and the European Union, which represents approximately 6 million people. Overall, heart disease is estimated to cost Europe €169 billion annually," said Paulita LaPlante, president and chief executive officer of Vasamed, in a news release.

"The AcQtrac system's rapid, noninvasive cardiovascular assessment can be a cost-effective alternative for a market focused on earlier diagnosis and treatment as part of its overall health policy objectives."

The AcQtrac System uses a graphical waveform that represents the mechanical function of the cardiovascular system and provides information to assess conditions such as congestive heart failure. It is also used to monitor treatment outcomes such as those provided by drug therapy.

Vasamed is a Minneapolis-based medical technology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.